Stable operation of the Chinese drug product manufacturing plant
First written in FY2016. 9 of 14 entries say "Advanced", first in FY2017. Latest entry: FY2026.
The whole theme swung hardest in 2022: 1 of 6 companies on the "Worse" side.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The subsidiary 大桐製薬（中国）有限責任公司 has currently obtained approval for 6 generic drug products developed in-house. Going forward, the company aims to further enhance its presence by participating in China's centralized procurement system and capturing the country's large market size and high growth potential.」
For the Chinese subsidiary, progress has been made from the previous stage of initial shipments and approval applications to obtaining approval for 6 proprietary generic drug products and adopting a policy of participating in China's centralized procurement system. - FY2025AdvancedAnnual report
「The subsidiary 大桐製薬(中国)有限責任公司 shipped its proprietary generic drug product, the pain treatment Pregabalin Capsules, to the Chinese market for the first time in May 2025, and has received additional orders steadily. It has also filed approval applications with the Chinese authorities for 1 additional proprietary generic drug product and several contract-manufactured products. The company is considering contract manufacturing of approximately 11 generic drug ingredients for the domestic Chinese market by the fiscal year ending May 2027, which is expected to become one of the Group's earnings pillars.」
The Chinese subsidiary achieved its first shipment of a proprietary generic drug product and received additional orders, and describes further approval applications and a plan to consider contract manufacturing of approximately 11 ingredients by the fiscal year ending May 2027. - FY2025-H1AdvancedAnnual report
「During the current interim consolidated accounting period, the company made additional investments in 千輝薬業（安徽）有限責任公司 and 安徽鼎旺医薬有限公司. As a result, the companies became associates and were included within the scope of application of the equity method.」
The company made additional investments in China's 千輝薬業 and 安徽鼎旺医薬, making both companies associates and bringing them within the scope of the equity method. - FY2024AdvancedAnnual report
「Against this backdrop, the Group is working to strengthen its capital and business alliance with 千輝薬業 and 鼎旺医薬, raising its equity interest from the current 12% to 21%. Going forward, it will strengthen sales of APIs and drug products in the Chinese market through strong collaboration with 千輝薬業 and 鼎旺医薬. The subsidiary 大桐製薬(中国)有限責任公司 has applied to the Chinese authorities for approval of 2 generic drug products for the domestic Chinese market. It is also considering contract manufacturing of approximately 11 generic drug ingredients for the domestic Chinese market by the fiscal year ending May 2027, which is expected to become one of the Group's earnings pillars.」
The company has made its initiatives and pipeline more specific, progressing from the Chinese subsidiary's stable operations and sales enhancement policy to raising its equity interests in 2 Chinese companies, filing approval applications for 2 products for the domestic Chinese market, and considering contract manufacturing of approximately 11 ingredients by the fiscal year ending May 2027. - FY2022RestatedAnnual report
「In China, the company's subsidiary 大桐製薬(中国)有限責任公司 also undertakes contract manufacturing for Japan. Going forward, the company plans to increase the number of products manufactured under contract, pursue sales in the Chinese market, achieve stable plant operations, and strengthen sales.」
While continuing its existing policy of contract manufacturing for Japan at the Chinese subsidiary, sales in the Chinese market, and stable plant operations, the company explicitly states that it will increase the number of contract-manufactured products and strengthen sales. - FY2018RestatedAnnual report
「In China, the company's subsidiary 大桐製薬(中国)有限責任公司 has begun contract manufacturing for Japan. Going forward, the company plans to achieve stable plant operations with a view to sales in the Chinese market.」
The company continues its policy of contract manufacturing for Japan at its Chinese subsidiary and stable plant operations with a view to sales in the Chinese market. - FY2017AdvancedAnnual report
「In China, the company's subsidiary 大桐製薬(中国)有限責任公司 has begun contract manufacturing for Japan. Going forward, the company plans to achieve stable plant operations with a view to sales in the Chinese market.」
It reports the specific progress of beginning contract manufacturing for Japan at the Chinese plant. The subsidiary also carried out a capital increase of USD 3 million in February 2017. - FY2016First statedAnnual report
「In China, a drug product manufacturing plant of the company's subsidiary 大桐製薬(中国)有限責任公司 was completed in November 2014. The company plans to achieve stable plant operations, with a view to both contract manufacturing for Japan and sales in the Chinese market.」
For the Chinese plant, the company is considering both contract manufacturing for Japan and sales in the Chinese market.